Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library

School of Medicine

9-22-2010

Exploring a therapeutic role for IGF1R inhibitors in
triple-negative breast cancer
Onyinye Offor

Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
Recommended Citation
Offor, Onyinye, "Exploring a therapeutic role for IGF1R inhibitors in triple-negative breast cancer" (2010). Yale Medicine Thesis Digital
Library. 120.
http://elischolar.library.yale.edu/ymtdl/120

This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.

Exploring a therapeutic role for IGF1R inhibitors in triple-negative breast
cancer

A Thesis Submitted to the
Yale University School of Medicine
in Partial Fulfillment of the Requirements for the
Degree of Doctor of Medicine

by
Onyinye Offor
2010

EXPLORING A THERAPEUTIC ROLE FOR IGF1R INHIBITORS IN TRIPLENEGATIVE BREAST CANCER
Onyinye Offor, Catherine Sullivan, Sofya Rodov, Kimberly Lezon-Geyda, Lyndsay
Harris. Section of Medical Oncology, Department of Internal Medicine, Yale University,
School of Medicine, New Haven, CT
SUMMARY
There is substantial preclinical and clinical data suggesting that triple-negative
breast cancer (TNBC), a breast cancer subtype that lacks HER-2, estrogen- and
progesterone-receptor expression is associated with obesity, insulin resistance and
metabolic derangements involving the insulin-like growth factor (IGF) pathway.

We

hypothesized that IGF-1 receptor (IGF1R) targeted therapy will be active in TNBC and
will enhance the activity of chemotherapeutic agents used for breast cancer. We aimed
(1) to determine if AG1024, an experimental tyrosine kinase inhibitor of IGF-1R, or
Figitumumab, a human anti-IGF1R antibody, has a cytotoxic effect on TNBC cell lines as
a single agent and (2) to determine if combining AG1024 or Figitumumab with
conventional chemotherapeutic agents, doxorubicin or paclitaxel, in TNBC cell lines
would enhance their cytotoxic effects.

To evaluate the effect of these agents,

cytotoxicity assays were conducted using four TNBC cell lines (MDA-MB-231, MDA-MB468, SUM149 and BT20) and a non-TNBC cell line, MCF7, for comparison.
Our results showed that AG1024 caused a dose-dependent decrease in cell
viability in TNBC cell lines and that TNBC cell lines were more sensitive to AG1024 than
non-TNBC cell lines. Also, the cytotoxic effects of AG1024 were enhanced in all TNBC
cell lines by the addition of paclitaxel and in three out of four TNBC cell lines upon
adding doxorubicin. Figitumumab monotherapy failed to have cytotoxic effects on TNBC
cell lines but the anti-IGF1R antibody cytotoxic effects were enhanced by addition of
doxorubicin in two TNBC cell lines and by addition of paclitaxel in one TNBC cell line.
This study suggests that therapies targeting the IGF1R may have clinical application in
the treatment of TNBC and tyrosine kinase inhibitors, such as AG1024, may be better
suited for treating TNBC than monoclonal antibodies.
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1. INTRODUCTION
Microarray profiling studies have led to the identification of distinct breast
cancer subtypes1. Breast malignancies are designated “triple-negative” when
immunohistochemical and fluorescence in situ hybridization testing reveals a lack
of HER2/neu expression, estrogen- and progesterone-receptor expression1. This
subtype of breast cancer frequently resembles the outer or basal layer of the
breast duct rather than the inner layer or lumen of the breast duct. However, the
triple-negative subtype is not synonymous with basal-like breast cancer. Basallike malignancies express one or more the basal cytokeratins (CK 5/6, CK14,
CK17 and CK903), laminin and fatty acid binding protein1. They also tend to be
estrogen-

and

progesterone-receptor

negative.

55-85%

of

basal-like

malignancies lack estrogen- and progesterone-receptor expression. Depending
on the study, between 65-90% of triple-negative tumors are basal-like. Clearly,
there are basal-like malignancies that are not triple-negative and vice-versa.
Triple-negative breast cancer (TNBC) accounts for 10-17% of all breast
cancer cases and is more prevalent in pre-menopausal African-American and
Hispanic women, compared to Caucasian and post-menopausal AfricanAmerican women2. Moreover, it carries a worse prognosis than its counterparts.
Up to 50% of patients will relapse and die of their disease even when it is
detected during its early stages3, 4. Furthermore, they cannot be treated with
therapies such as tamoxifen or trastuzumab (Herceptin) that have significantly
improved outcomes in estrogen receptor-positive or HER-2 positive breast
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cancer patients, respectively.

Therefore, it is imperative to identify novel

therapies for this patient population.
Although the exact pathogenesis of TNBC is not clear, TNBC is more
common in women with an elevated waist-hip ratio5 and increased body mass
index (BMI)6. Obesity, defined as a body mass index (BMI) 30kg/m2, is an
established risk factor for breast cancer in post-menopausal women and
prognostic factor in both pre- and post-menopausal women7, 8. Obesity causes
changes in steroid metabolism that directly or indirectly contribute to breast
carcinogenesis; one of these consequences is the up-regulation of insulin and
insulin-like growth factors (IGFs)9,
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. This suggests that abnormalities in

metabolism may be implicated in the development of TNBC.
Insulin receptors (IRs) were first detected on mammary carcinoma
samples and shown to bind insulin in 197711. Insulin receptors and insulin-like
growth factor receptors (IGFRs) are both tetrameric tyrosine kinases found on
the cell surface. These tetramers are comprised of two half-receptors consisting
of an extracellular -chain that mediates ligand binding and an intracellular chain that contains the tyrosine kinase domain. The gene encoding the insulin
receptor can be differentially spliced to yield the fetal splice variant, IRA, or the
classic adult isoform, IRB12-14.

IRA is thought to be involved in growth and

proliferation whereas IRB is associated with carbohydrate metabolism15.
In vitro studies have shown that insulin, at physiologic concentrations, stimulates
DNA synthesis and thus cell proliferation in breast cancer cells16, 17. In patients
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with hyperinsulinemia, prospective studies have shown that women with insulin
levels in the highest quartile have twice the risk of recurrence and triple the
mortality risk from all breast cancer subtypes, compared to women with normal
insulin levels18. Type II diabetics with breast cancer are known to have more
rapid disease progression and approximately 40% increase in 5-year mortality
due to their breast cancer19.

Of note, 1,1-dimethylbiguanide hydrochloride

(Metformin), an anti-diabetic drug that stabilizes glucose flux and reduces
insulin resistance via activation of the AMP-kinase dependent pathway, lowers
insulin levels by 22% in early stage breast cancer patients20 and improves
survival in diabetic cancer patients21. Also, higher pathologic complete response
rates are observed in diabetics who take Metformin compared to those who do
not (24% versus 8%)22. Finally, Metformin inhibits cellular proliferation and
induces apoptosis in TNBC in vitro and in vivo23. These effects have not been
demonstrated in non-TNBC cell lines.
Given the common ancestry and similarities in the signaling pathways
downstream of the insulin and insulin-like growth factor 1 receptor (IGF1R), the
associations between elements of the IGF axis and carcinoma have also become
of interest to the scientific community.

The insulin-like growth factor (IGF)

ligands I and II play important roles in the regulation of cellular proliferation,
differentiation and survival. They are primarily synthesized in the liver and both
bind to IGF1R to exert their effects via the RAS-MAPK and PI3K pathways.
IGF2R, on the other hand, does not appear to transmit proliferation and survival
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signals; rather, it seems to sequester the ligands and thereby act as a negative
regulator of the pathway. Of note, IRs and IGF1R can form hybrid receptors;
malignant neoplasms have been shown to preferentially express IRA-IGF1R
hybrid receptors

24, 25

. Several landmark studies have also shown that IGF1R is

implicated in mitogenesis, malignant transformation, invasion and resistance to
some anticancer therapies particularly those that target the ER and the epidermal
growth factor receptor (EGFR) members, EGFR26 and HER227.
By 1984, in vitro studies had shown IGF I and II have mitogenic activity in
breast carcinoma cell lines28. In 1987, IGF1R was detected in primary human
breast carcinoma specimens29. As early as 1989, blockade of the IGF1R using
-IR-3, a monoclonal antibody, was proven to inhibit growth in vitro and thwart
the mitogenic effect of IGF-I in breast cancer cell lines. Of note, -IR-3 inhibited
the growth of TNBC in nude mice but failed to act similarly in estrogen-receptor
positive breast cancer cells30.
Several studies have also attempted to correlate expression of IGF
components with prognosis in breast cancer patients.

Initially, high IGF1R

expression was believed to be a favorable prognostic factor31. In a series of 184
breast cancer specimens, the average IGF1R content was nearly ten times
higher in breast carcinomas than in normal breast tissue and IGF1R levels were
significantly higher in the low-risk group (ER+/PR+) than in high-risk individuals
(ER-/PR-). However, a recent study by Law et al32 suggests that detection of
phosphorylated IGF1R (p-IGF1R), not total IGF1R, better predicts survival and is
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associated with poor prognosis. They evaluated 438 cases of invasive breast
cancer using p-IGF1R antibody on tumor tissue microarrays. Their data suggest
that p-IGF1R rather than total IGF1R was indicative of survival and that p-IGF1R
was detected in all subtypes of breast cancer represented in their cohort (triplenegative 41.9%, luminal 48.1%, HER2 64.3%). An IGF-I molecular signature
associated with poor disease outcome and negative prognostic factors has also
been postulated. Through in vitro stimulation of breast cancer cells with IGF-I,
Creighton et al defined an expression pattern of over 800 genes that were either
up- or down-regulated. Analysis of gene expression in clinical breast tumors
revealed that ER-negative tumors displayed high expression of genes induced by
IGF-I and low expression of genes repressed by IGF-I33.
Despite evidence suggesting a role for IGFs and IGF1R in breast
carcinoma, it was not until the beginning of the 21st century that the
pharmaceutical industry began to manufacture therapies targeted to IGF1R34.
There are two main classes of anti-IGF1R therapies: receptor-specific antibodies
and receptor kinase inhibitors.
(Figitumumab:

IGF1R-specific antibodies include CP-751871

Pfizer), AMG479 (Amgen), h10h5 (Genentech), AVE1642

(Sanofi-Aventis), A12 (Imclone), MK0646 (Merck) and R1507 (Roche) and BMS536924 (Bristol Myers Squibb).

AG538 and AG1024 (3-bromo-5-t-butyl-4-

hydroxy-benzylidenemalonitrile) are two of the IGF1R tyrphostins, receptor
tyrosine kinase inhibitors, which have been developed. AG1024 is only used
experimentally and has not been tested in humans.
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AG1024 binds to the active site of both IGF1R and IR to induce conformational
changes that prevent substrates such as IRS-1 and ATP from binding to the
receptors.

It has a lower affinity for IR and a lower IC50 for IGF1R (7M for

IGF1R compared to 57M for IR35).

Early studies of AG1024 in hormone

receptor-positive and TNBC cell lines have shown that as a single agent, it is
effective at reducing proliferation and inducing apoptosis36-38. Using hormone
receptor-positive MCF7 cells, Chakraborty et al showed that combining -IR3, a
murine anti-IGF1R monoclonal antibody or AG1024, an IGF1R tyrosine kinase
inhibitor, with anti-estrogen reagents leads to greater growth inhibition than using
these reagents alone39. Other studies have corroborated these findings40.
Initial studies of Figitumumab in breast cancer were conducted using
MCF7, an estrogen- and progesterone-receptor positive breast carcinoma cell
line41. Figitumumab binds to the extracellular domain of IGF1R homodimers and
heterodimers; it does not cross-react with IR.

Furthermore, consecutive

immunoblots showed that culturing MCF7 cells with 1g/mL of Figitumumab
caused a time-dependent decrease in IGF1R with maximal effect attained
between 3 and 4 hours of exposure. Confocal microscopy also revealed that the
same concentration of Figitumumab induced internalization of IGF1R receptors
within 15 minutes of exposure. In tumor xenograft models using MCF7 cells,
Figitumumab alone inhibited tumor growth and when combined with tamoxifen,
an anti-estrogen therapy for estrogen-receptor positive patients, inhibited tumor
growth more than Figitumumab or tamoxifen alone41. A similar effect was
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produced when Figitumumab and doxorubicin (Adria) were combined in
3T3/IGF1R-transfected tumors41.
In recent clinical trials involving patients with multiple myeloma, lung
cancer or other solid tumors, several agents have induced responses when
acting as single-agents and the IGF1R antibodies generally have a favorable
toxicity profile42, 43. These antibodies cause increases in the serum concentration
of human growth hormone and IGF-I but there is no evidence to suggest that
increases in IGF-I can overcome the suppression caused by IGF1R inhibitors42.
To date, clinical trials of IGF1R targeted therapies in breast cancer include a
Phase I trial of neoadjuvant Figitumumab in early stage, operable breast cancer
(ClinicalTrials.gov identifier: NCT006352) and a Phase I trial of Figitumumab and
Pegvisomant, a growth hormone antagonist, in advanced solid tumors
(ClinicalTrials.gov identifier: NCT00976508).
Although there is evidence that antagonizing IGF1R in TNBC may be of
clinical benefit, most of the studies involving the newly developed IGF1R
antibodies have focused on hormone receptor-positive breast cancer models and
there are few preliminary studies of IGF1R antibodies in TNBC or TNBC cell
lines. A recent study by Zha et al40 examined the effect of h10H5, an anti-human
IGF1R monoclonal antibody, in several hormone receptor-positive and TNBC cell
lines. The cell lines that showed sensitivity to h10H5 were primarily ER-positive
with intermediate to high levels of IGF1R expression.

MCF7, a hormone

receptor-positive breast carcinoma cell line, was shown to respond to h10H5
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whereas MDA-MB-231 and MDA-MB-468, two TNBC negative cell lines failed to
show sensitivity to this agent. Nonetheless, the proliferation of three ER-negative
cell lines (HCC1143, HDQP1 and SW527) with low to intermediate IGF1R
expression was inhibited by h10H5.
Our study proposes to evaluate the activity of IGF1R receptor antibodies
and the tyrophostin, AG1024, in TNBC cell lines to explore the therapeutic
potential of these agents in this breast cancer subtype. In this study, we will
investigate TNBC cell lines that were not represented in previously published
studies. Finally, we will explore the potential for IGF1R targeted therapies to
enhance the cytotoxicity of conventional chemotherapeutic agents that are the
mainstay of treatment for TNBC patients. In this study, we combine doxorubicin,
an anthracycline that interferes with DNA synthesis, and paclitaxel, a taxane that
stabilizes microtubules, with Figitumumab and AG1024 to determine if greater
cellular inhibition is achieved using these conventional chemotherapeutic agents
with IGF1R antagonists.
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2. PURPOSE AND HYPOTHESIS
There is substantial preclinical and clinical data suggesting that TNBC is
associated with obesity, insulin resistance and metabolic derangements
(involving IGF and IGF1R). We hypothesize that IGF1R targeted therapy will be
active in TNBC cell lines and will enhance the activity of chemotherapeutic
agents used for breast cancer.

3. SPECIFIC AIMS
Specific Aim #1:

To confirm that AG1024, an experimental tyrosine kinase

inhibitor of IGF-1R, has an anti-proliferative effect on TNBC cell lines as a single
agent.

Specific Aim #2: To determine if Figitumumab, a human anti-IGF1R antibody
targeting the extracellular domain of the receptor, has an anti-proliferative effect
on TNBC cell lines as a single agent.

Specific Aim #3: To determine if AG1024 has an additive cytotoxic effect when
combined with conventional chemotherapeutic agents, doxorubicin or paclitaxel,
in TNBC cell lines.

Specific Aim #4: To determine if Figitumumab has an additive cytotoxic effect
when combined with conventional chemotherapeutic agents, doxorubicin or
paclitaxel, in TNBC cell lines.
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Specific Aim #5: To compare the effects of AG1024 and Figitumumab on TNBC
cell lines with their effects on an ER- and PR-positive breast cancer cell line,
MCF7 (alone or in combination with chemotherapeutic agents).

Specific Aim #6: To compare the relative levels of IGF1R expression in the
TNBC and hormone-receptor positive cell lines utilized in this study and
determine if total IGF1R expression correlates with response to IGF1R-targeted
agents.
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4. MATERIALS AND METHODS
Cell Culture
TNBC cell lines (MDA-MB-231, MDA-MB-468, BT-20) were maintained in RPMI
1640 supplemented with 10% fetal bovine serum (FBS), L-glutamine, sodium
pyruvate and gentamicin.

SUM-149 was maintained in F-12 media containing

5g/mL insulin, 1g/mL hydrocortisone, 10mM or 1% HEPES, 5% FBS and
gentamicin. The MCF-7 cell line was maintained in Dulbecco’s Modified Eagles
Medium (DMEM) supplemented with 10% fetal bovine serum, L-glutamine,
sodium pyruvate, 7g/mL insulin and gentamicin. All reagents were purchased
from Invitrogen except HEPES and hydrocortisone which were purchased from
Sigma. All cell lines were cultured in a 37C humidified atmosphere containing
95% air and 5% CO2.

Reagents
AG1024, an IGF1R tyrosine kinase inhibitor (Calbiochem: San Diego, CA), was
dissolved in 164L of DMSO to prepare a 20mM stock solution. This solution
was stored at -20C.

CP-751871 (Figitumumab) was given as part of

collaboration with Dr. Michael DiGiovanna (Yale Cancer Center) and was
received as a stock solution of 6.1mg/mL stored at 4C.

Paclitaxel (Taxol:

Bristol Myers Squibb, Princeton, NJ) and doxorubicin (Adria: Adria Laboratories
Incorporated, Columbus, OH) were stored at concentrations of 7mM and
2mg/mLrespectively. Paclitaxel was stored at room temperature and doxorubicin
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was stored at 4C. All of the stock solutions were diluted in OptiMEM (Invitrogen)
prior to their addition to the cells.

Western Blotting
All cell lines were trypsinized, centrifuged and washed in PBS with EDTA-free
protease inhibitor cocktail (Roche: Indianapolis, IN). Cells were centrifuged, PBS
was aspirated and the cell pellet was stored at -80C. After thawing the frozen
pellet, the cells were resuspended in 100-120L of CelLytic M lysis reagent
(Sigma-Aldrich, St Louis, MO) containing protease inhibitor cocktail (Roche).
This mixture was sonicated on ice for 10 seconds then incubated for 15 minutes
at 4C followed by centrifugation at maximum speed for 15 minutes at 4C. A
standard curve was calibrated using BSA (2g/L). Nine microliters of distilled
water and 200L of BioRad protein assay dye were added to 1L of each sample
to calculate each sample protein concentration. 10L of lysis buffer and Laemmli
sample buffer was added to 30g of protein from each cell line. These mixtures
were boiled for 5 minutes then cooled on ice for 5 minutes and proteins were
separated on Bio-Rad Ready 4-20% Tris-HCl gels. Proteins were separated on
an SDS-PAGE 4-20% Tris-HCl gel (Bio-Rad: Hercules, CA). Proteins were then
transferred onto a nitrocellulose membrane (Bio-Rad) in a transfer buffer
containing 20% methanol. Western blot analysis was performed with anti-IGF1R
antibody (Cell Signaling Technology: Danvers, MA) and appropriate secondary
antibodies. Images were taken on a ChemiDoc XL (Bio-Rad).
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Cell Proliferation Assays
To determine the optimal concentration of cells per well for 5-day drug assays, a
proliferation assay was performed for each cell line. All cell lines were harvested,
resuspended in OptiMEM and plated in triplicate in 96-well plates at four or more
different concentrations of cells per well. Cells were allowed to adhere for 24
hours then 10L of Cell Proliferation Reagent, WST-1 (Roche Diagnostics:
Mannheim, Germany), was added to each well. Plates were incubated for 2
hours when optical density at 450nm was determined using a microplate reader
(EL-800 Universal microplate reader: Bio-Tek instruments, Vinooski, VT). The
WST-1 colometric assay was performed daily and a proliferation curve was
produced using the readings from Days 0-5. The optimal cell concentration at
Day 0 was defined as the concentration at which cells remain in the log phase of
growth on Day 5. One thousand cells/well was estimated as the optimal
concentration for MCF7 and BT-20 cells.

Fifteen hundred cells/well was

estimated to be the optimal concentration for MDA-MB-231 cell line.

Three

thousand cells/well was estimated to be the optimal concentration for MDA-MB468 and SUM149 cells.

Cytotoxicity Assays
A. All cells were harvested, resuspended in OptiMEM and plated in triplicate in
96-well plates at their optimal concentration. After a 24-hour incubation period at

14
37C, drugs were added to the cells. Cells were not confluent at the time drug
was added. Five concentrations of each drug were tested in triplicate. Paclitaxel
was used at 0.2nM, 2nM, 20nM, 200nM and
2000nM. AG1024 and doxorubicin were tested at 0.01M, 0.1M, 1M, 10M
and 100M.

Figitumumab was tested at 0.1M, 1M, 10M, 100M and

1000M. The WST-1 colormetric assay was performed on Day 5. The optical
densities of the controls (the cells not exposed to the drugs) were averaged to
obtain the mean. This number represented 100% survival of cells. The percent
of surviving cells in each well containing drug was calculated using the following
equation: (optical density in drug-treated well / average optical density of the
controls) x 100. For each drug concentration, the average of the three calculated
percentages represented the percent of surviving cells for that concentration.
The half maximal inhibitory concentration was calculated using GraphPad
Prism (GraphPad Software Incorporated: La Jolla, CA).

B. All cell lines were harvested, resuspended in OptiMEM and plated at the
optimal concentration of cells per well. After a 24-hour incubation period, drugs
were added as needed in each well. On Day 5, a WST-1 colormetric assay was
performed to determine the cytotoxicity of the drug(s) on the cells. Calculations
were performed as previously described under IC50 determination assays. For
each concentration, the mean  two standard deviations are reported. P-values
were calculated using an unpaired t-test.
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5. RESULTS
Expression of IGF1R in MCF7 (hormone receptor-positive) and triplenegative breast cancer cell lines.
Western blots were performed to compare the relative total IGF1R
expression levels in MCF7, MDA-MB-231, MDA-MB-468, BT-20 and SUM149
cell lines (Figure 1). As expected, BT-20 cell lines exhibited the highest levels of
total IGF1R44. An intermediate level of expression was noted in MCF7 cells while
MDA-MB-468 and SUM-149 cells expressed the lowest levels of IGF1R. MDAMB-231 total IGF1R expression was not analyzed due to loss of the cell lysate,
however, other studies have shown that MDA-MB-231 has a similar expression
to MDA-MB-46840.

AG1024 inhibits the proliferation of hormone receptor-positive and TNBC
cells in a dose-dependent fashion.
Dose-response curves were generated to demonstrate the effect of
AG1024, an IGF1R tyrosine kinase inhibitor, on each cell line.

AG1024

significantly inhibited the proliferation of the MDA-MB-231 (Fig. 2B), MDA-MB468 (Fig. 2C) and SUM149 (Fig. 2E) cell lines in a dose-dependent manner
(<30% cell viability when incubated with 40M AG1024). AG1024 also caused
intermediate growth inhibition in BT20 (Fig. 2D) cells (<40% cell viability when
incubated with 40M AG1024) and was least effective in MCF7 (Fig. 2A) cells
(<60% cell viability when incubated with 40M AG1024.)
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Figitumumab, when used as a single agent, has no anti-proliferative activity
in hormone receptor-positive and triple-negative breast cancer cell lines.
Dose-response curves were generated to demonstrate the effect of
Figitumumab, an IGF1R targeted antibody, on each cell line (Figure 3).

At

concentrations ranging from 0M to 0.585M, Figitumumab had no discernible
inhibitory effect on the proliferation of MCF7, MDA-MB-231, MDA-MB-468, BT20
and SUM149 cells.

AG1024 enhances the anti-proliferative activity of doxorubicin in MDA-MB231, MDA-MB-468 and SUM149 triple-negative breast cancer cell lines.
AG1024 was combined with doxorubicin to determine if it had an additive
effect on the anti-proliferative action of paclitaxel. Bar graphs depicting the effect
of AG1024 alone and in combination with doxorubicin were created for each cell
line.

Drug combinations were interpreted to cause additive or enhanced

cytotoxicity if the combination caused a statistically significant decrease in cell
viability compared to either drug alone.
The proliferation of MCF7 cells was not inhibited by any of the tested doxorubicin
concentrations. When 1M AG1024 was used alone, it was associated with 90%
cell viability (6%, 95% CI), however when either 0.01M or 0.05M doxorubicin
was added, the combination led to an 11% decrease in cell viability. When 1M
AG1024 was combined with 0.1M doxorubicin there was no evidence of additive
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cytotoxicity. Hence, the observed additive cytoxicity at lower doses is modest
and not consistent at all dose ranges (Figure 4A).
In contrast, there was a dramatic decrease in cell viability of MDA-MB-231
cells when increasing concentrations of doxorubicin were added to 1M AG1024
(Figure 5A). Doxorubicin alone at 0.01M resulted in 84% cell viability (2%, 95%
CI) and 1M AG1024 alone led to 67% cell viability (8%, 95% CI). However,
adding 0.01M doxorubicin to 1M AG1024 led to 45% cell viability (8%,
p=0.002) whereas adding 0.05M doxorubicin produced 20% cell viability (2%,
p=0.001 for 1M AG1024 alone versus combined with 0.05M doxorubicin).
Combining 0.05M doxorubicin with 1M AG1024 produced the same level of
inhibition as that achieved by 0.4M doxorubicin used as monotherapy.
Growth of MDA-MB-468 cells was inhibited by doxorubicin in a dosedependent manner. A decrease in cell viability was appreciated when 0.05M
doxorubicin was added to 1M AG1024 (Figure 6A). Incubating MDA-MB-468
cells with only 0.05M doxorubicin led to approximately 48% cell viability.
Incubation of cells with 1M AG1024 alone caused 48% cell viability (5%)
compared to 23% (1%) when 0.05M doxorubicin was added. It is possible that
there is an enhanced cytotoxic effect when 1M AG1024 is combined with
0.01M doxorubicin but this effect may have been obscured by the variation and
wide standard deviation among the replicates of the 0.01M doxorubicin assay.
Additive cytotoxic effects were also observed to a lesser degree when comparing
5M AG1024 alone (40%1%) to 5M AG1024 plus 0.01M doxorubicin
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(34%4%, p=0.006) and 5M AG1024 plus 0.05M doxorubicin (29%4%,
p=0.001).
In BT20 cells, doxorubicin monotherapy caused growth inhibition only at
the highest concentration tested - 0.4M led to 75% cell viability 15%.
Enhancement of AG1024’s effect was observed when 1M AG1024 was
combined with 0.1M doxorubicin (Figure 7A). This combination caused 80%
cell viability (2%) compared to 93% cell viability (5%) when 1M of AG1024
was used alone or 94% cell viability (6%,) when 0.1M of doxorubicin was used
alone. However, a higher concentration of doxorubicin (0.2M) failed to produce
additive cytotoxicity with 1M AG1024 and inhibited cell viability to a lesser
extent than 0.1M doxorubicin plus 1M AG1024. These findings suggest that
the optimal dose-range for AG1024 and doxorubicin is likely to be achievable in
vivo.
In SUM149 cells, 80% cell viability (3%) was seen when 1M AG1024
was used alone and 59% cell viability (7%) was noted when 0.2M doxorubicin
alone was used. Cell viability decreased to 45% (1%) when 0.2M doxorubicin
was combined with 1M AG1024. Addition of doxorubicin to 5M and 10M
AG1024 failed to produce greater inhibition of cell proliferation than 5M or 10M
AG1024 alone (Figure 8A).
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AG1024 enhances the anti-proliferative activity of paclitaxel in MDA-MB231, MDA-MB-468, BT-20 and SUM149 triple-negative breast cancer cell
lines.
AG1024 was combined with paclitaxel to determine if it had an additive
effect on paclitaxel’s anti-proliferative action. Bar graphs depicting the effect of
AG1024 alone and in combination with paclitaxel were created for each cell line.
The proliferation of MCF7 cells was not inhibited by any of the tested paclitaxel
concentrations and there was no increase in cytotoxicity when paclitaxel and
AG1024 were combined (Figure 4B).
Paclitaxel inhibited the growth of all triple negative cell lines in a dosedependent manner and enhanced cytotoxicity with combinations of paclitaxel and
AG1024 was observed in all of the triple-negative cell lines (Figures 5B-8B). In
MDA-MB-231 cells, incubation with 1M AG1024 alone led to 67% cell viability
(8%). Treatment with 1.136nM and 2.27nM paclitaxel alone resulted in 93% cell
viability (16%) and 54% cell viability (9%), respectively. Compared to 1M
AG1024 alone, adding 1.136nM and 2.27nM paclitaxel resulted in an 18%
decrease (11%, p=0.008) and 36% decrease in MDA-MB-231 cell viability
(7%, p=0.0003), respectively. Combining 5M AG1024 with 1.136nM paclitaxel
failed to produce greater growth inhibition than 5M AG1024 alone in MDA-MB231 cells. However, 49% cell viability (4%) was seen after treatment with 5M
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AG1024 alone compared to 28% cell viability (8%, p=0.001) after incubation
with 5M AG1024 and 2.27nM paclitaxel.

In MDA-MB-468 cells, treatment with 1.136nM paclitaxel failed to inhibit
cell proliferation while using 2.27nM paclitaxel alone caused 69% cell viability
(10%.) Incubation with 1M AG1024 alone led to 48% cell viability (5%) and
adding 2.27nM paclitaxel to 1M AG1024 caused a decrease to 30% cell viability
(2%). Also, adding 1.136nM paclitaxel to 5M AG1024 led to a 7% decrease in
cell viability (40%1% using 5M AG1024 alone compared to 33%1% when
combined with 1.136nM paclitaxel) and adding 2.27nM led to an 11% decrease
in cell viability (3%).
Paclitaxel also inhibited the growth of BT20 cells with increasing doses
and additive cytotoxicity was observed between the lowest dose of paclitaxel and
the two highest concentrations of AG1024 (Figure 7B). Treating BT20 cells with
1.136nM paclitaxel alone resulted in 79% cell viability (3%). Treating these
cells with 5M AG1024 alone caused 57% cell viability (1%) whereas adding
1.136nM paclitaxel led to 51% cell viability (4%, p=0.03).

Similarly, 10M

AG1024 alone resulted in 57% cell viability (3%) but with addition of 1.136nM
paclitaxel, the cell viability fell to 51% (2%, p=0.005).
In SUM149 cells, enhanced cytotoxicity was evident with multiple
combinations of paclitaxel and AG1024 (Figure 8B). Treatment of SUM149 cells
with 1M AG1024 alone led to 80% cell viability (3%) and incubation with
1.136nM paclitaxel alone resulted in 69% cell viability (11%); adding 1.136nM
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paclitaxel to 1M AG1024 further inhibited cell viability to 53% (p=0.04 for
1.136nM paclitaxel alone versus combined with 1M AG1024). Treatment of

SUM149 cells with 5M AG1024 alone produced 49% cell viability (4%) and
adding 1.136nM paclitaxel led to 36% cell viability (1%, p=0.004 for 5M
AG1024 alone versus combined with 1.136nM paclitaxel). Combinations of 10M
AG1024 and paclitaxel also provided evidence of increased cytotoxicity when the
two compounds were combined. 10M AG1024 alone caused 34% cell viability
(2%) whereas adding 1.136nM paclitaxel led to 28% cell viability.

Using

concentrations of paclitaxel greater than 1.136nM in combination with any dose
of AG1024 led to approximately the same level of cellular growth inhibition.

Figitumumab enhances the anti-proliferative activity of doxorubicin in
MCF7, MDA-MB-468 and SUM149 breast cancer cell lines.
Figitumumab was combined with doxorubicin to determine if it had an
additive effect on the anti-proliferative action of doxorubicin.

Bar graphs

depicting the effect of Figitumumab, a targeted IGF1R antibody, alone and in
combination with doxorubicin were created for each cell line (Figures 4C-8C).
Neither

doxorubicin

nor

Figitumumab

significantly

inhibited

the

proliferation of MCF7 cells as single agents at any of the tested concentrations
(Figure 4C). However, increased cytotoxicity was appreciated when 0.175M
Figitumumab was combined with 0.05M doxorubicin.

Adding 0.05M
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doxorubicin to 0.175M Figitumumab caused cell viability to decrease by 11%
(6%, p=0.005).

The proliferation of MDA-MB-231 and MDA-MB-468 cells was inhibited by
doxorubicin alone (0.05μM-0.4μM); however, Figitumumab alone did not inhibit
proliferation of these cell lines (Figures 5C and 6C respectively).

Increased

cytotoxicity was noted when 0.175μM or 0.585μM of Figitumumab was combined
with 0.05μM of doxorubicin in MDA-MB-468 cells (47%4% and 43%3% cell
viability, respectively compared to 81%26 cell viability when 0.05 μM of
doxorubicin was used alone.)
Doxorubicin and Figitumumab combinations also increased cytotoxicity in
SUM149 cells. Treatment with 0.01M doxorubicin alone did not inhibit cellular
proliferation.

Treatment with 0.1M and 0.2M doxorubicin alone caused

approximately 100% cell viability, 85% cell viability (7%) and 59% (7%)
respectively. When treated with 0.0585μM Figitumumab alone, SUM149 cells
did not experience inhibition of cell proliferation but adding 0.01μM, 0.1μM and
0.2μM doxorubicin led to 88% (11%), 54% (4%) and 35% (4%) cell viability,
respectively (Figure 8C).

Adding doxorubicin to 0.175μM Figitumumab and

0.585μM Figitumumab led to cell viability levels similar to those seen with
0.0585μM Figitumumab. An enhanced cytotoxic effect was not appreciated in
MDA-MB-231 or BT-20 cells with any combinations of Figitumumab and
doxorubicin.
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Figitumumab enhances the anti-proliferative activity of paclitaxel in the
MCF7 and MDA-MB-231 breast cancer cell lines.
Figitumumab was combined with paclitaxel to determine if it had an
additive effect on paclitaxel’s anti-proliferative action. Bar graphs depicting the
effect of Figitumumab alone and in combination with paclitaxel were created for
each cell line.
As single agents, paclitaxel and Figitumumab did not inhibit the
proliferation of MCF7 cells. However, increased cytotoxicity was detected at all
concentrations of Figitumumab when either 2.27nM or 9.09nM paclitaxel was
added (Figure 4D). The addition of 2.27nM or 9.09nM paclitaxel to 0.0585μM
Figitumumab both caused a 30% decrease in cell viability (9%). When the
same concentrations of paclitaxel were used in combination with 0.175μM
Figitumumab, a 23-26% decrease in cell viability was noted.

Combining

0.585μM Figitumumab with 2.27nM or 9.09nM paclitaxel led to approximately 1319% decrease in cell viability.
Paclitaxel alone significantly inhibited the proliferation of MDA-MB-231
and MDA-MB-468 cells (2.27nM-18.18nM, Figures 5D and 6D) as well as BT20
and

SUM149

cells

(1.136nM-18.18nM,

Figures

7D

and

Figitumumab alone did not inhibit proliferation of these cells.

8D)

whereas

However, the
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lowest and intermediate concentrations of Figitumumab (0.0585μM and
0.175μM) had an increased cytotoxic effect when combined with 2.27nM
paclitaxel in MDA-MB-231 cells (52%6% and 56%9%, respectively compared
to 69%1 with 2.27nM paclitaxel alone.) This effect was not discerned in MDAMB-468, BT20 or SUM149 cells.
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6. DISCUSSION
The primary aim of this study was to explore whether antagonizing the
IGF1R in triple-negative breast cancer models is a useful therapeutic strategy.
The association between triple-negative breast cancer, obesity and metabolic
derangements involving the IGF1R pathway make IGF1R a logical target. To
examine the activity of IGF1R antagonists in triple-negative breast cancer cell
lines, we performed cytoxicity assays using AG1024, an IGF1R tyrosine kinase
inhibitor, and Figitumumab, an IGF1R specific antibody, as single agents. As
triple-negative patients are often treated with doxorubicin or paclitaxel, two
chemotherapeutic agents, cytoxicity assays testing combinations of these
reagents with doxorubicin or paclitaxel were also performed. Although AG1024
has been studied in triple-negative breast cell lines, there are no studies
documenting the effect of Figitumumab in these breast cancer cell lines.
Furthermore, no prior publications have explored if enhanced cytotoxicity is
achieved when IGF1R inhibitors are combined with doxorubicin or paclitaxel in
TNBC cell lines.
Our results indicate that AG1024 effectively inhibits the proliferation of
both hormone receptor-positive and TNBC cell lines. However, in our study,
AG1024 produced higher levels of inhibition in TNBC cell lines, compared to the
ER- and PR-positive cell line, MCF7. After treatment with 40M AG1024, MCF7
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cells exhibited 52% cell viability whereas treatment of MDA-MB-231 cells, MDAMB-468, BT20 and SUM149 cells resulted in 15%, 26%, 34% and 18% cell
viability, respectively. Cell lines with the highest level of IGF1R expression

(MCF7 and BT20) were least sensitive to AG1024 whereas the cell lines with
relatively low levels of IGF1R expression were the most sensitive to AG1024
(MDA-MB-231, MDA-MB-468 and SUM149.)
Evidence of additive cytotoxic effects due to AG1024 and doxorubicin
combinations was seen in MDA-MB-231, MDA-MB-468 and SUM149 triplenegative cell lines.

Additive cytotoxicity was evident when the lowest

concentration of AG1024 (1M) was combined with the lowest concentration of
doxorubicin (0.01M) in MDA-MB-231 cell lines. However, this concentration of
doxorubicin did not increase cytotoxicity when added to 1M AG1024 in MDAMB-468 and SUM149 cell lines. A higher concentration of doxorubicin, 0.05M
in MDA-MB-468 cell lines and 0.2M in SUM149, was needed to produce
additive cytotoxic effects. Also, MDA-MB-468 cells were the only cell line to
exhibit this effect when 5M AG1024 was combined with doxorubicin. The dose
of doxorubicin at which additive cytotoxic effects are elicited appears to depend
on the cell line’s sensitivity to doxorubicin.

The cell lines that were more

sensitive to doxorubicin (MDA-MB-231 and MDA-MB-468) exhibited increased
cytotoxicity with AG1024 at a lower concentration of doxorubicin.
Of note, the cell lines with the highest IGF1R expression levels (MCF7
and BT20) did not exhibit enhanced cytotoxicity with combinations of AG1024
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and doxorubicin. In this study, the proliferation of MCF7 cells was not inhibited
after treatment with concentrations of doxorubicin ranging from 0.01M to 0.4M.

Our findings are consistent with other studies that have shown an IC50 as high
as 5M doxorubicin for MCF7 cells45.
Combinations of AG1024 and paclitaxel only produced increased
cytotoxicity in the TNBC cell lines. The proliferation of all the TNBC cell lines
was inhibited by paclitaxel alone.

The cell lines that were most sensitive to

AG1024 (MDA-MB-231, MDA-MB-468 and SUM149) exhibited increased
cytotoxicity due to AG1024 and paclitaxel at the lowest concentration of AG1024
(1M) whereas the cell lines that were less sensitive to AG1024 (BT20)
demonstrated this effect with a higher dose of AG1024 (5M) but not with the
lowest dose of AG1024 (1M). Treatment with 1.136nM paclitaxel alone failed to
inhibit MDA-MB-468 proliferation while cell viability fell to 93% in MDA-MB-231
cells and approximately 80% in BT20 and SUM149 cells. Of note, the lowest
concentration of paclitaxel, 1.136nM, increased cytotoxicity in all cell lines
regardless of their sensitivity to paclitaxel. In this study, concentrations of
paclitaxel ranging from 1.136nM to 18.18nM failed to inhibit the cellular
proliferation of MCF7 cells. These findings are corroborated by studies that have
demonstrated an IC50 as high as 200nM for MCF7 cells45.
Figitumumab, when used as a sole agent, did not inhibit cell proliferation
regardless of hormone receptor status.

However, there was evidence of
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increased cytotoxicity due to combinations of Figitumumab and doxorubicin or
paclitaxel.

At the lowest concentration of Figitumumab that we tested

(0.0585M), Figitimumab enhanced the cytotoxic effects of both low and high

concentrations of doxorubicin in SUM149 cells.

In MCF7 cells, this effect

between Figitumumab and doxorubicin was evident at an intermediate dose of
Figitumumab (0.175M) and an intermediate dose of doxorubicin (0.05M). A
similar response was noted in MDA-MB-468 cells which demonstrated increased
cytotoxicity when intermediate to high doses of Figitumumab (0.175M and
0.585M) were combined with an intermediate dose of doxorubicin (0.05M.)
Of note, even though MDA-MB-468 cells were the most sensitive to
doxorubicin when used as a single agent, an intermediate dose of doxorubicin
was needed to elicit increased cytotoxicity with Figitumumab.

In contrast,

SUM149 cells were slightly less sensitive to doxorubicin than MDA-MB-468 cells
yet they demonstrated this response at low and high doses of doxorubicin.
Therefore, doxorubicin sensitivity did not predict the concentration at which
doxorubicin and Figitumumab combinations would enhance cytotoxicity in our
study.
Sensitivity to doxorubicin alone also did not predict whether doxorubicin
and Figitumumab would enhance cytotoxicity. For instance, MDA-MB-231 cells
were sensitive to doxorubicin when used as a single agent. Doxorubicin at
0.01M failed to inhibit the proliferation of MDA-MB-231 cells but 0.05M
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doxorubicin caused the cell viability to drop sharply to 39%. However, there was
no discernible increase in cytotoxicity due to Figitumumab and doxorubicin

combinations in MDA-MB-231 cells whereas MCF7 cells that failed to respond to
doxorubicin as a single agent, exhibited this effect.
In MCF7 and MDA-MB-231 cells, Figitumumab enhanced the antiproliferative activity of paclitaxel.

In MCF7 cells, this effect was noted at all

concentrations of Figitumumab and intermediate concentrations of paclitaxel. In
MDA-MB-231 cells, increased cytotoxicity was noted when low and intermediate
concentrations of Figitumumab were combined with a low concentration of
paclitaxel. Of note, sensitivity to paclitaxel did not predict that increased
cytotoxicity would occur with Figitumumab and paclitaxel combinations since
MDA-MB-468, BT20 and SUM149 cells were sensitive to paclitaxel alone but
failed to experience enhanced cytotoxic effects with Figitumumab and paclitaxel
combinations.
This study demonstrates that antagonizing IGF1R is effective in inhibiting
the proliferation of several triple-negative breast cancer cell lines. AG1024, a
receptor tyrosine kinase inhibitor, appeared to be more effective as a single
agent than Figitumumab, an IGF1R specific antibody. Moreover, our data show
that combining AG1024 with paclitaxel enhanced the anti-proliferative activity of
AG1024 in all the TNBC cell lines . This effect was not as striking in the hormone
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receptor-positive cell line, MCF7. Furthermore, combinations of AG1024 and
doxorubicin caused additive cytotoxicity in three out of four TNBC cell lines.
The toxicity of doxorubicin and paclitaxel are well-documented. Significant
adverse reactions associated with doxorubicin include acute or delayed

cardiotoxicity,

colon

necrosis,

gastrointestinal

ulceration

and

infertility.

Paclitaxel’s side effects include peripheral neuropathy (seen in up to 70% of
patients), nausea, vomiting, mucositis and increases in creatinine and liver
enzymes.

Decreasing the amount of doxorubicin or paclitaxel used in

chemotherapy regimens is a desirable goal since it could reduce the risk of
adverse reactions and improve the quality of life of patients.
Although Figitumumab did not inhibit proliferation as a single agent,
addition of doxorubicin caused additive cytotoxicity in MCF7 cells and one TNBC
cell lines. Combining Figitumumab and paclitaxel improved Figitimumab’s ability
to antagonize cell proliferation in hormone receptor-positive MCF7 cells and two
TNBC cell lines.
Our investigation is a preliminary study of IGF1R antagonists alone and in
combination with chemotherapy in TNBC cell lines. Limitations of this study
include the small number of cell lines employed.

Testing other TNBC and

hormone receptor-positive breast cancer cell lines, besides those used in this
study, is required to further elucidate the effect of AG1024 and Figitumumab on
these subtypes of breast cancer. In addition, each cytotoxicity assay was will
need to be repeated several times in order to ensure that the results we obtained
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are reproducible.

Furthermore, analysis of IGF1R expression after treatment

with AG1024 and Figitumumab (alone and in combination with chemotherapy)
would also provide useful data about the effect of targeted IGF1R therapies.
Overall, our findings suggest that there is a role for IGF1R antagonism in the
treatment of TNBC and that kinase inhibitors, like AG1024, may be more
effective agents than anti-IGF1R monoclonal antibodies.
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SUM149

BT20

MCF7

MDA-MB468

7. FIGURE REFERENCES AND LEGENDS

100 kD
80kD
60kD

Figure 1: Total IGF1R protein expression in breast carcinoma cell lines. 30g of
protein from each cell line was loaded on BioRad Ready 4-20% Tris-HCl gel. Western
blots were perfomed by Sofya Rodov (SR). IGF1R, a 95 kiloDalton protein, was
detected in each of the cell lines. BT-20 cell lines exhibited the highest levels of total
IGF1R44. An intermediate level of expression was noted in MCF7 cells while MDA-MB468 and SUM-149 cells expressed the lowest levels of IGF1R. MDA-MB-231 total IGF1R
expression was not analyzed due to loss of the cell lysate, however, other studies have
shown that MDA-MB-231 has a similar expression to MDA-MB-46840
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MDA-MB-231: AG1024
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MDA-MB-468: AG1024
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BT-20: AG1024
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SUM149: AG1024
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Figure 2E
Figure 2A-E: Effect of AG1024, a tyrosine kinase inhibitor of IGF1R, on MCF7 (2A),
a hormone receptor positive breast cancer cell line and triple-negative breast
cancer cell lines, MDA-MB-231(2B), MDA-MB-468(2C), BT20 (2D) and SUM149
(2E).

Cells were seeded at their optimal concentration in 96 well plates then

allowed to adhere overnight. AG1024 was added the following day (Day 0). After 5
days of incubation, the WST-1 assay was performed. Each point represents the
percent of surviving cells compared to control (cells not exposed to AG1024). The
mean of three wells 2SD (95% CI) is shown. AG1024 decreased the viability of all
cell lines in a dose-dependent fashion. The MCF7 cell line was the least sensitive
to AG1024. Assays in Figures 2A-2C were executed by Onyi Offor (OO). Assays
in Figures 2D-2E were executed jointly by OO and SR.
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BT20: Figitumumab
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SUM149: Figitumumab
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Figure 3E

Figure 3A-E: Effect of Figitumumab, an IGF1R targeted antibody, on MCF7 (3A), a
hormone receptor positive breast cancer cell line and triple-negative breast cancer
cell lines, MDA-MB-231 (3B), MDA-MB-468(3C), BT20 (3D) and SUM149 (3E).
Cells were seeded at their optimal concentration in 96 well plates then allowed to
adhere overnight. Figitumumab was added the following day (Day 0). After 5 days
of incubation, the WST-1 assay was performed. Each point represents the percent
of surviving cells compared to control (cells not exposed to Figitumumab.) The
mean of three wells 2SD (95% CI) is shown. Figitumumab monotherapy failed to
have a cytotoxic effect in all of the cell lines. Assay in Figure 3A, 3D and 3E was
executed by SR. Assays in Figures 3B and 3C were executed by OO.
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MCF7: Doxorubicin ± Figitumumab
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Figure 4: Effect of AG1024, an IGF1R tyrosine kinase inhibitor, and Figitumumab, an
IGF1R targeted antibody, alone and in combination with conventional chemotherapeutic
agents, doxorubicin and paclitaxel, in MCF7 cells. Cells were plated at 1000 cells/well
and allowed to adhere overnight. Drugs were applied the next day (Day 0). WST-1
assay was performed on Day 5. Each bar represents the average of three wells  2SD
(95% CI). Doxorubicin or paclitaxel concentrations increase along the x-axis. Each
color represents a different concentration of AG1024 or Figitumumab tested (blue bars =
0M AG1024 in Figs. 4A and 4B or 0M Figitumumab in Figs. 4C and 4D, maroon bars
= 0.01M doxorubicin in Figures 4A and 4B or 0.0585M Figitumumab in Figures 4C
and 4D and so forth).

Increased cytotoxicity was seen with combinations of

Figitumumab and AG1024 (Fig. 4C) and Figitumumab and paclitaxel (Fig. 4D.)
Fig. 4C:

Adding 0.05M doxorubicin to 0.175M Figitumumab caused cell

viability to decrease by 11% (6%, p=0.005) compared to using 0.175M Figitumumab
alone.
Fig. 4D:

Increased cytotoxicity was detected at all concentrations of

Figitumumab when either 2.27nM or 9.09nM paclitaxel was added (Figure 4D). The
addition of 2.27nM or 9.09nM paclitaxel to 0.0585μM Figitumumab both caused a 30%
decrease in cell viability (9%). When the same concentrations of paclitaxel were used
in combination with 0.175μM Figitumumab, a 23-26% decrease in cell viability was
noted.

Combining 0.585μM Figitumumab with 2.27nM or 9.09nM paclitaxel led to

approximately 13-19% decrease in cell viability. Assays in Figures 4A and 4D were
executed by OO and SR respectively. Assays in Figures 4B and 4C were executed
jointly by OO and SR.
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Figure 5B
MDA-MB-231: Doxorubicin ± Figitumumab
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MDA-MB-231: Taxol ± Figitumumab
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Figure 5D
Figure 5: Effect of AG1024, an IGF1R tyrosine kinase inhibitor, and Figitumumab, an
IGF1R targeted antibody, alone and in combination with conventional chemotherapeutic
agents, doxorubicin and paclitaxel, in MDA-MB-231 cells. Cells were plated at 1500
cells/well and allowed to adhere overnight. Drugs were applied the next day (Day 0).
WST-1 assay was performed on Day 5. Each bar represents the average of three wells
 2SD (95% CI). Each color represents a different concentration of AG1024 or
Figitumumab tested (blue bars = 0M AG1024 in Figs. 5A and 5B or 0M Figitumumab
in Figs. 5C and 5D, maroon bars = 0.01M doxorubicin in Figures 5A and 5B or
0.0585M Figitumumab in Figures 5C and 5D and so forth). Figitumumab monotherapy
failed to cause a decrease in cell viability. Combining AG1024 and doxorubicin (Figure
5A), AG1024 and paclitaxel (Fig. 5B) as well as Figitumumab and paclitaxel (Fig. 5D)
showed an increased cytotoxic effect compared to these agents alone.
Fig. 5A: Doxorubicin alone at 0.01M resulted in 84% cell viability (2%, 95%
CI) and 1M AG1024 alone led to 67% cell viability (8%, 95% CI). However, adding
0.01M doxorubicin to 1M AG1024 led to 45% cell viability (8%, p=0.002) whereas
adding 0.05M doxorubicin produced 20% cell viability (2%, p=0.001 for 1M AG1024
alone versus combined with 0.05M doxorubicin).
Fig. 5B:

Compared to 1M AG1024 alone, adding 1.136nM and 2.27nM

paclitaxel resulted in an 18% decrease (11%, p=0.008) and 36% decrease in MDA-MB231 cell viability (7%, p=0.0003), respectively. Combining 5M AG1024 with 1.136nM
paclitaxel failed to produce greater growth inhibition than 5M AG1024 alone in MDAMB-231 cells. However, 49% cell viability (4%) was seen after treatment with 5M
AG1024 alone compared to 28% cell viability (8%, p=0.001) after incubation with 5M
AG1024 and 2.27nM paclitaxel.
Fig. 5D: The addition of 2.27nM or 9.09nM paclitaxel to 0.0585μM Figitumumab
both caused a 30% decrease in cell viability (9%). When the same concentrations of
paclitaxel were used in combination with 0.175μM Figitumumab, a 23-26% decrease in
cell viability was noted.

Combining 0.585μM Figitumumab with 2.27nM or 9.09nM

paclitaxel led to approximately 13-19% decrease in cell viability. Assays in Figures 5C
and 5D were executed by OO and SR respectively. Assays in Figures 5A and 5B were
executed jointly with SR and OO
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Figure 6: Effect of AG1024, an IGF1R tyrosine kinase inhibitor, and Figitumumab, an
IGF1R targeted antibody, alone and in combination with conventional chemotherapeutic
agents, doxorubicin and paclitaxel, in MDA-MB-468 cells. Cells were plated at 3000
cells/well and allowed to adhere overnight. Drugs were applied the next day (Day 0).
WST-1 assay was performed on Day 5. Each bar represents the average of three wells
 2SD (95% CI). Each color represents a different concentration of AG1024 or
Figitumumab tested (blue bars = 0M AG1024 in Figs. 6A and 6B or 0M Figitumumab
in Figs. 6C and 6D, maroon bars = 0.01M doxorubicin in Figures 6A and 6B or
0.0585M Figitumumab in Figures 6C and 6D and so forth). Combining AG1024 and
doxorubicin (Figure 6A) and Figitumumab and doxorubicin (Fig. 6C) showed an
increased cytotoxic effect compared to these agents alone.
Fig. 6A: Treating MDA-MB-468 cells with only 0.05M doxorubicin or only 1M
AG1024 led to approximately 48% cell viability compared to 23% (1%) when 1M
AG1024 and 0.05M doxorubicin were combined (Fig. 6A). Additive cytotoxic effects
were also observed to a lesser degree when comparing 5M AG1024 alone (40%1%)
to 5M AG1024 plus 0.01M doxorubicin (34%4%, p=0.006) and 5M AG1024 plus
0.05M doxorubicin (29%4%, p=0.001).
Fig. 6C:

Increased cytotoxicity was noted when 0.175μM or 0.585μM of

Figitumumab was combined with 0.05μM of doxorubicin in MDA-MB-468 cells (47%4%
and 43%3% cell viability, respectively compared to 81%26 cell viability when 0.05 μM
of doxorubicin was used alone.) Assays in Figures 6A, 6C and 6D were executed by
OO. Assay in Figure 6B was executed jointly by OO and SR.
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Figure 7: Effect of AG1024, an IGF1R tyrosine kinase inhibitor, and Figitumumab, an
IGF1R targeted antibody, alone and in combination with conventional chemotherapeutic
agents, doxorubicin and paclitaxel, in BT20 cells. Cells were plated at 1000 cells/well
and allowed to adhere overnight. Drugs were applied the next day (Day 0). WST-1
assay was performed on Day 5. Each bar represents the average of three wells  2SD
(95% CI). Color-coding of the bars is similar to that described in Figs. 4-6. Combining
AG1024 and paclitaxel (Fig. 7B) showed an increased cytotoxic effect compared to
these agents alone. Treating BT20 cells with 1.136nM paclitaxel alone resulted in 79%
cell viability (3%).

Treating these cells with 5M AG1024 alone caused 57% cell

viability (1%) whereas adding 1.136nM paclitaxel led to 51% cell viability (4%,
p=0.03). Similarly, 10M AG1024 alone resulted in 57% cell viability (3%) but with
addition of 1.136nM paclitaxel, the cell viability fell to 51% (2%, p=0.005). Assays in
Figures 7A and 7D were executed by OO and SR respectively. Assays in Figures 7B
and 7C were executed jointly by OO and SR.
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SUM149: Taxol ± Figitumumab
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Figure 8D
Figure 8: Effect of AG1024, an IGF1R tyrosine kinase inhibitor, and Figitumumab, an
IGF1R targeted antibody, alone and in combination with conventional chemotherapeutic
agents, doxorubicin and paclitaxel, in SUM149 cells. Cells were plated at 3000 cells/well
and allowed to adhere overnight. Drugs were applied the next day (Day 0). WST-1
assay was performed on Day 5. Each bar represents the average of three wells  2SD
(95% CI). Color-coding of the bars is similar to that described in Figs. 4-6. Combining
AG1024 and doxorubicin (Figure 8A), AG1024 and paclitaxel (Fig. 8B) and Figitumumab
and doxorubicin (Fig. 8C) showed an increased cytotoxic effect compared to these
agents alone.
Fig. 8A: Cell viability decreased to 45% (1%) when 0.2M doxorubicin was
combined with 1M AG1024 compared to 80% cell viability (3%) when 1M AG1024
was used alone or 59% cell viability (7%) 0.2M doxorubicin monotherapy was used.
Fig. 8B: Combining 1.136nM paclitaxel with any concentration of AG1024 led to
enhanced cytotoxic effects compared to either reagent alone. Treatment of SUM149
cells with 1M AG1024 alone led to 80% cell viability (3%) and incubation with 1.136nM
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paclitaxel alone resulted in 69% cell viability (11%); adding 1.136nM paclitaxel to 1M
AG1024 further inhibited cell viability to 53% (p=0.04 for 1.136nM paclitaxel alone versus
combined with 1M AG1024). Treatment of SUM149 cells with 5M AG1024 alone
produced 49% cell viability (4%) and adding 1.136nM paclitaxel led to 36% cell viability
(1%, p=0.004 for 5M AG1024 alone versus combined with 1.136nM paclitaxel).
Treatment using 10M AG1024 alone caused 34% cell viability (2%) whereas adding
1.136nM paclitaxel led to 28% cell viability. Treatment with 0.01M or 0.05M
doxorubicin alone did not inhibit cellular proliferation but treatment with 0.1M and
0.2M doxorubicin alone caused approximately 85% cell viability (7%) and 59% (7%)
respectively.
Fig. 8C: When treated with 0.0585μM Figitumumab alone, SUM149 cells did not
experience inhibition of cell proliferation but adding 0.01μM, 0.1μM and 0.2μM
doxorubicin led to 88% (11%), 54% (4%) and 35% (4%) cell viability, respectively
(Figure 8C). Assays in Figures 8A and 8D were executed by OO and SR respectively.
Assays in Figures 8B and 8C were executed jointly by OO and SR. Doxorubicin and
Figitumumab combinations also increased cytotoxicity in SUM149 cells.
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